Avantor Inc. (AVTR) Stock Forecast & Price Target

Avantor is showing a credible turnaround as total organic growth returned to +5.2%, with both segments outperforming and VWR delivering its best result in recent memory at ~5.8% organic growth, while BMP also returned to positive growth at +3.6%. The fundamental case is strengthened by self-help initiatives—revived branding, e-commerce gains, faster onboarding, and operational improvements—alongside improving end-market conditions in pharma, biotech funding, and NIH stabilization, which could support further demand recovery. Even with profitability still pressured, adjusted EBITDA of $256.9M at a 15.1% margin and raised FY'26 organic growth, EPS, and free cash flow guidance suggest management is executing better and the turnaround is gaining traction.

Avantor is facing a protracted and uncertain recovery in scientific lab supply, where investors have already endured years of false starts and demand normalization may still not arrive, while Thermo Fisher’s share gains add competitive pressure. Its growth profile also looks structurally weaker because a large part of Bioscience and Medtech depends on process chemicals and fluid handling units, which are not expanding at the bioprocess industry’s +HSD pace amid operational challenges and possible AI-driven shifts away from wet-lab research. Margin recovery is similarly limited, with adjusted operating margins in the low-teens versus prior mid-teens and an earlier high-teens aspiration, and above-average debt, funding uncertainty, tariffs, and geopolitical risks further justify a discounted outlook.